MedCity News
SEPTEMBER 8, 2022
Medical IoT is forecast to grow from $41 billion in 2020 to $188 billion by 2028. The growth is for a good reason: Connected medical devices, combined with the right software, can improve conditions and delivery, optimize care and devices, and save lives.
Pharmaceutical Technology
SEPTEMBER 8, 2022
Roche has signed a definitive merger agreement for the acquisition of US-based biopharmaceutical company Good Therapeutics for an upfront payment of $250m in cash. Good Therapeutics focuses on the development of PD-1-regulated IL-2 drugs that are based on innovative conditionally active drug technology. With the takeover, Roche will attain rights to a conditionally active, PD-1-regulated IL-2 programme of Good Therapeutics.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MedCity News
SEPTEMBER 8, 2022
Through the collaboration, UnitedHealth Group’s Optum will use its analytics and support tools to help Walmart Health clinicians deliver value-based care to Medicare Advantage beneficiaries. The partnership is starting at 15 locations in Florida and Georgia with the potential to grow in the future.
pharmaphorum
SEPTEMBER 8, 2022
Asking patients with chronic conditions to regularly inject themselves can be challenging, causing needle anxiety and worry that they may not carry out the procedure correctly, which can reduce compliance. Now, a partnership between Ypsomed and Sidekick Heath aims to tackle that problem. Ypsomed is a top developer of injection and infusion systems, so knows a lot about the difficulties that patients can face when getting to grips with these medical devices, particularly when they are just starti
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
MedCity News
SEPTEMBER 8, 2022
uMETHOD, which provides precision medicine software to treat cognitive decline, tapped at-home diagnostics provider Getlabs to supply mobile phlebotomies for its patients in Arizona. Blood tests are an essential part of the personalized care plans that uMETHOD provides, and the partnership seeks to make these tests accessible to patients with cognitive decline.
European Pharmaceutical Review
SEPTEMBER 8, 2022
Comparing the use of common antiretroviral therapy (ART) regimens in pregnancy suggests that dolutegravir-based regimens have a higher probability of human immunodeficiency virus type 1 (HIV-1) viral suppression at delivery. In a study published in the New England Journal of Medicine , researchers compared the effectiveness and safety of dolutegravir-based ART to five ART regimens recommended for use in pregnancy in the US and Europe: atazanavir–ritonavir, darunavir–ritonavir, oral rilpivirine,
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
pharmaphorum
SEPTEMBER 8, 2022
Ben Hargreaves examines what advantages radiopharmaceuticals offer in the treatment of cancer and why there has been interest from big pharma in developing these types of therapies. The article also outlines some of the challenges remaining to be tackled. Radiotherapy dates back more than a hundred years, yet it still remains a core part of cancer treatment today.
MedCity News
SEPTEMBER 8, 2022
We’re faced with unprecedented headwinds. Many rural and community practices and hospitals have scaled back their services to maintain some level of operations. Technology can help organizations navigate these headwinds and position themselves for future success.
European Pharmaceutical Review
SEPTEMBER 8, 2022
“The most exciting finding of the study is the robustness of the signal in the cluster-interval data,” noted co-author and Assistant Professor of Neurology at Harvard Medical School, US, Dr Jurriaan Peters. “The results consistently showed a clinical and statistical increase in the time between use of intranasal diazepam, Valtoco, over time.
MedCity News
SEPTEMBER 8, 2022
The HLTH conference has much to offer startups and investors at the early and growth stage, from networking opportunities, turnkey exhibits, compelling content, pitch contests, an Innovators’ Reception, exclusive pricing and more. Register today!
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
PharmaVoice
SEPTEMBER 8, 2022
Supply chain challenges, labor shortages and increased FDA inspections are boosting recall risks — but careful planning can keep companies in the clear.
MedCity News
SEPTEMBER 8, 2022
The Office of the Inspector General issued a special fraud alert in July concerning telehealth fraud, […].
Teachntest
SEPTEMBER 8, 2022
Advertisement Dipane Tablets Uses, Benefits & Side Effects Dipane Tablet is a pain-relieving medicine containing Diclofenac and Paracetamol. It is used to treat rheumatoid arthritis, ankylosing spondylitis, and osteoarthritis by reducing pain and inflammation. Additionally, it can be used to relieve muscle pain, back pain, toothache, and ear and throat pain.
MedCity News
SEPTEMBER 8, 2022
Alira Health hopes its purchase of RedCrow will help it stand out from the crowd of consulting firms that help life sciences companies bring drugs to market.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
Teachntest
SEPTEMBER 8, 2022
Advertisement Mehanil Tablets Uses and Benefits Mehanil Tablets are considered an effective treatment for blood sugar management. Type 2 diabetes is a prevalent condition that affects a substantial portion of the population. Despite the possibility of genetic causes for diabetes, lifestyle choices play a significant role in uncontrolled blood sugar levels.
MedCity News
SEPTEMBER 8, 2022
Roche announced it will acquire Good Therapeutics, a Seattle-based preclinical biotech, for $250 million. The deal makes Roche responsible for developing and commercializing Good’s lead program, which seeks to make oncology drugs that target PD-1 proteins more effective, such as Keytruda or Opdivo.
pharmaphorum
SEPTEMBER 8, 2022
A malaria vaccine developed by members of the University of Oxford team behind the AstraZeneca COVID-19 jab has been hailed as a possible game-changer in the fight against the deadly parasitic infection. Hopes were already running high for the R21/Matrix-M vaccine after it showed 77% protective efficacy over 12 months in a phase 2b trial involving young west African children that was reported last year – meeting the World Health Organisation’s efficacy goal of 75% – after an initial three-
PharmExec
SEPTEMBER 8, 2022
Barnes discusses alternative reimbursement plans for expensive, one-off therapies.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
PharmaTimes
SEPTEMBER 8, 2022
Collaboration involves the marketing and distribution of PreHevbri across Europe
Copyright Clearance Center
SEPTEMBER 8, 2022
The post Exploring the Challenges in the Shift to Open Access: Part 1 – Data appeared first on Copyright Clearance Center.
PharmaTech
SEPTEMBER 8, 2022
In partnership with the University of Pittsburgh, ElevateBio will open its next manufacturing center in the city.
InCrowd
SEPTEMBER 8, 2022
InCrowd conducted 2 surveys to 209 attending physicians and 454 medical residents to understand what their perspective is regarding the status of diversity training and education they receive and what their experiences are in the professional environment. In the next few articles, we’ll discuss the responses and findings of these surveys. There was a significant tip towards male responders as opposed to female, transgender men, transgender women, non-binary, and those who preferred not to answer
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
Legacy MEDSearch
SEPTEMBER 8, 2022
Serpex Medical announced U.S. FDA 510(k) clearance of its Compass Steerable Needles – steerable biopsy needles that enable precise access to lung nodules in the intrapulmonary region. Serpex Medical seeks to leverage the power of steerable instruments to enable greater precision and access to improve the diagnosis and treatment of lung cancer. The clearance of the Compass Steerable Needles follows the recent clearance of Serpex’s Recon Steerable Sheath. “The Compass steerable needle
pharmaphorum
SEPTEMBER 8, 2022
Germany’s Merck KGaA paid $237 million upfront for rights to Debiopharm’s head and neck squamous cell carcinoma (HNSCC) therapy xevinapant last year in a deal valued at more than $1 billion, and it now has further data suggesting it was a solid deal. At the ESMO cancer congress which gets underway in Paris tomorrow, Merck will report results from a phase 2 study which according to the drugmaker is the first in decades to show a significant improvement in overall survival in patients
Curzon Consulting
SEPTEMBER 8, 2022
8th September 2022 2 Minutes There is little evidence that greenhouse gas emissions can be decoupled from economic growth in absolute terms from an environmental perspective. Since economic growth is one of the main drivers for rising emissions (and increasing depletion of non-renewable resources), it seems evident that a transition to degrowth would make an essential contribution to climate change mitigation, and hence to our moral obligation to preserve future generations’ rights to basi
Pharmaceutical Technology
SEPTEMBER 8, 2022
The US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to AceLink Therapeutics’ AL01211 to treat Fabry disease. A glucosylceramide synthase (GCS) inhibitor, AL01211 has high potency, increased selectivity and other beneficial drug properties that support once-a-day oral dosing. Additionally, it provides a much-required oral small molecule treatment as a substitute to existing therapies for Fabry disease, which need repeated intravenous dosing. .
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Curzon Consulting
SEPTEMBER 8, 2022
8th September 2022 1 Minutes There are incredible synergies with aligning purpose and ambition in the decarbonisation sense to the Mission, Vision and Values of the business. Thinking of them in unison will intertwine the business plan (revenue generation) with the decarbonisation plan and allow the business to set short and long-term business goals and decarbonisation metrics.
pharmaphorum
SEPTEMBER 8, 2022
The Digital Medicine Society (DiME) is today releasing a new set of open-access resources to advance the use of nocturnal scratch in the treatment of atopic dermatitis (AD). . Night-time flare-ups of AD being especially painful and worrying, notably in children who suffer from it, nocturnal scratch aims to offer “new ways of measuring night-time scratching, using new digital tools [to] improve measurement of this distressing facet of AD”.
Curzon Consulting
SEPTEMBER 8, 2022
8th September 2022 1 Minutes Renewables will represent 80% of the total share of investments in power generating capacity from today to 2050. Global energy needs are expected to grow by 30% between today and 2040. . As an asset class, renewable energy has matured dramatically over the past two decades. It has gone from being seen as an alternative culture to having huge investment potential.
pharmaphorum
SEPTEMBER 8, 2022
On the strength of phase 2 data, the FDA has awarded coveted breakthrough status to Pfizer’s vaccine against Group B Streptococcus (GBS), given to expectant mothers to prevent invasive infections in newborns and young infants. The data from the ongoing study hasn’t yet been made public, but an interim analysis was enough to convince the US regulator that Pfizer’s GBS6 (PF-06760805) should be granted the designation, which could accelerate its passage through regulatory review.
Advertisement
The global landscape of clinical trials is rapidly changing as studies become more complex. An increasing number of sponsors are seeking enhanced flexibility in their supply chains to address a variety of clinical supply challenges, including patient demand and reducing delays. Demand-led supply and direct-to-patient distribution are next-generation solutions that are helping to meet these growing needs, allowing for more streamlined processes and patient-centric studies.
Expert insights. Personalized for you.
127 
Let's personalize your content